Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Millendo Therapeutics Announces Appointment of Christopher J. Seiter as Chief Financial Officer

Thursday, November 17, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

ANN ARBOR, Mich., Nov.17, 2016 – Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced the appointment of Christopher J. Seiter as its Chief Financial Officer. Mr. Seiter will join Millendo’s senior management team and will be responsible for the finance, treasury and accounting functions of the Company. Mr. Seiter joins Millendo from Bank of America Merrill Lynch.


“We are delighted to welcome Chris to our management team. He has extensive experience in corporate finance and has advised a wide variety of biopharmaceutical companies as they developed their pipelines and commercialized their products,” said Julia C. Owens, Ph.D., President and Chief Executive Officer of Millendo. “His expertise will be instrumental to the development and implementation of our financial strategy as we continue to progress our product candidates in four endocrine disease areas.”


Prior to joining Millendo, Mr. Seiter served as a Managing Director at Bank of America Merrill Lynch in the firm’s healthcare investment banking group. In this capacity, he advised life sciences companies and facilitated transactions ranging from equity and debt financings to mergers and acquisitions. During his 17-year tenure there, Chris held various roles of increasing responsibility, including Head of Life Sciences Investment Banking. Prior to that, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Before his career in investment banking, Mr. Seiter served in the U.S. Navy as a nuclear submarine officer for five years. Mr. Seiter earned a B.A. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Naval Nuclear Power School.


“I am thrilled to join Millendo at this important time in the Company’s growth,” commented Mr. Seiter. “This is an exciting opportunity to utilize my background in corporate finance to provide guidance and leadership as the Company advances its pipeline of novel medicines for patients with endocrine diseases that have few or no approved therapies.”


About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases caused by hormone dysregulation. We are currently advancing two product candidates to treat four diseases. Based on our understanding of the novel biology underlying hormone dysregulation in endocrine diseases, we are developing our product candidates for conditions where current therapies are insufficient. Our clinical programs are designed to address:


· Polycystic Ovary Syndrome (PCOS) – the most common endocrine disease in women

· Classic Congenital Adrenal Hyperplasia (CAH) – a recessive genetic defect of cortisol synthesis

· Endogenous Cushing’s Syndrome (CS) – a condition resulting from chronic cortisol excess

· Adrenocortical Carcinoma (ACC) – a rare endocrine malignancy of the adrenal cortex





Media Contact:

Casey R. Doucette, Ph.D.

MacDougall Biomedical Communications

+1 781 235 3060


Investor Contact:

Christina Tartaglia

Stern Investor Relations, Inc.

+1 212 362 1200

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal